ATS View
한국어

Dongsung Pharmaceutical KRX:002210KOSPI

동성제약 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h9
Articles, 7 days9
DART filings, 7 days0
Articles tracked13since Sep 11

In Q2 2026, Dongsung Pharmaceutical reported revenue of ₩22.1bn, up 10.6% year on year, and an operating loss of ₩2.0bn. Dongsung Pharmaceutical (동성제약) appeared in 9 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 30 with 9 articles. The most common catalyst was risk & warnings (9).

Filing signals Litigation Screener

Dongsung Pharmaceutical quarterly results separate, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩22.1bn+10.6%−₩2.0bn
margin −9.2%		−₩5.9bn
Q1 2026₩19.1bn-27.4%₩289m
margin 1.5%		₩14m
Q4 2025 derived₩19.1bn-15.5%−₩7.1bn
margin −37.3%		−₩5.8bn
Q3 2025₩21.8bn+1.7%₩411m
margin 1.9%		₩112m
Q2 2025₩20.0bn-8.2%−₩4.2bn
margin −20.8%		−₩18.8bn
Q1 2025₩26.3bn+16.0%₩743m
margin 2.8%		−₩1.3bn
Q4 2024 derived₩22.6bn+3.8%−₩3.1bn
margin −14.0%		−₩11.9bn
Q3 2024₩21.4bn-2.8%−₩698m
margin −3.3%		−₩1.5bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Dongsung Pharmaceutical top stories 2 weeks, by number of outlets

  1. 1
    '300억원대 횡령·시세조종'…동성제약 전 경영진들 불구속 송치
    5 outlets · 5 articlesFirst report Oct 30 16:38 머니투데이Negative news
  2. 2
    경찰, '회삿돈 300억대 횡령 혐의' 동성제약 전 경영진 송치
    3 outlets · 3 articlesFirst report Oct 30 17:13 뉴스1Negative news
  3. 3
    경찰, ‘300억 원대 횡령 혐의’ 동성제약 前 임직원들 불구속 송치
    1 outlets · 1 articlesFirst report Oct 30 17:30 서울경제Negative news

Latest Dongsung Pharmaceutical news Korean headlines